A Phase 4 interventional study of Beta blocker in Myocardial Infarction, sponsored by Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III. Completed at 111 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-06.
Sponsored by Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing Beta blockers in Myocardial Infarction — 3 open to participants now, 3 under way, none of them phase 3. A drug class: Beta blockers · Myocardial Infarction.
Among the 10 studies testing Beta blockers in Myocardial Infarction, this one is one of 2 that started in 2018, is one of 7 in phase 4, and was the 6th registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →3 of the 10 studies testing Beta blockers in Myocardial Infarction are open now, in 2 countries. Recruiting first, the newest first:
Vastra Gotaland Region · Sites in Sweden
Ages 18+
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation · Sites in Russian Federation
Ages 18+
Spanish Society of Cardiology
Ages 18–90
By country, each count listing its studies:
A class of medicines: which ones, and the studies of each, are on its page →
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 1977; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8,505 is above the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 600 across the 9 interventional studies. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 10 has an industry lead sponsor. The 10 most frequent:
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III has 5 studies filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing Beta blockers in Myocardial Infarction, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
REBOOT clinical trial will study whether long-term maintenance beta-blockers therapy results in a clinical benefit after heart attack without reduced left ventricular function. Half of the participants will be randomized to receive long-term beta-blocker therapy and the other half to no beta-blocker therapy after hospital discharge. All patients will be followed up for up to 5 years to determine the occurrence of adverse events (all cause mortality, re-infarction, and heart failure admission).
Pragmatic, controlled, prospective, randomized, open-label, blinded endpoint clinical trial testing the benefits of beta-blocker maintenance therapy in patients discharged after an acute myocardial infarction (MI). Patients being discharged after an acute MI, with or without ST-segment elevation, and with a left ventricular ejection fraction >40%, and without history of heart failure (HF) prior to study inclusion, will be recruited. At discharge, patients will be randomized (1:1) to receive beta-blocker therapy (agent and dose according to treating physician) or no beta-blocker therapy. Primary outcome is the 5 years incidence of MACE (all cause mortality, reinfarction, heart failure admission).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is a strategy (pragmatic) trial. In patients allocated to "Beta-blocker therapy", beta blocker agent and dose are decided by treating physician. betablocker therapy chosen might be any of the following: atenolol bisoprolol carvedilol metoprolol nebivolol
Drug: Beta blocker
Do not receive beta -blocker therapy
long-term maintenance beta-blocker therapy
Also known as: atenolol, bisoprolol, carvedilol, metoprolol, nevibolol.
Incidence rate of the composite of "all-cause death, nonfatal reinfarction, or heart failure hospitalization" (MACE)
absolute number of patients experiencing deaths will be added to number of patients experiencing a non fatal reinfarction and to number of patients experiencing heart failure hospitalization. If a patient experience more than one of these events, only first event will be added for the sum of events EXAMPLE events in arm 1: 150 deaths+150 reinfarctions+150 heart failure hospitalizations= TOTAL 450 MACE (450 events/4234 patients enroled: event rate 10.63%)
Time frame: 12-54 months since the beginning (median follow up anticipated 3.75 years)
2.1 Incidence rate of individual components of the primary outcome. 2.2 Incidence rate of cardiac mortality. 2.3 Incidence of sustained ventricular tachycardia/ventricular fibrillation (VT/VF) and resuscitated cardiac arrest.
Absolute number of events (% from total patients recruited) of the components of the MACE (eg number of all cause deaths (% from patients included) in active arm vs control). First event of each individual component counts for secondary outcome. EXAMPLE all cause death events in in arm 1: 200 deaths (200 events/4234 patients enroled: event rate 4.72%). nonfatal reinfarctions in in arm 1: 150 reinfarctions (150 events/4234 patients enroled: event rate 3.54%). note that in the example of the primary outcome, only 150 deaths are counted and for the secondary outcome 200. This is because in this hypothetical case, 50 deaths occurred in patients who previously experienced a nonfatal reinfarction
Time frame: 12-54 months since the beginning (median follow up anticipated 3.75 years)
3.1 Incidence of revascularizations during follow-up 3.2 Composite of cardiac death, stroke or myocardial infarction. 3.3 Safety endpoints 3.4 Quality of life and functional status (telephone evaluation):
3.1: Absolute number of patients undergoing a revascularization procedure during follow-up (% from total patients recruited) note: revascularizations that were scheduled at patients' discharge inclusion WILL NOT be considered an event 3.2: absolute number of patients experiencing cardiac death will be added to number of patients experiencing a stroke and to number of patient experiencing a non fatal reinfarction. If a patient experience more than one of these events, only first event will be added for the sum of events 3.3 3.3.1: Incidence of admission for symptomatic advanced atrioventricular (AV) block (Mobitz II or third degree). Absolute number of patients admitted for symptomatic AV block (% from total patients recruited) 3.3.2: Incidence of hospital admission for stroke: Absolute number of patients admitted for a stroke during follow-up (% from total patients recruited) 3.4 EQ-5D questionnaire (0-100, 100 best) IIEF-5 quest (5-25, 25 best) PHQ-2 questionnaire (0-6, 6 worst)
Time frame: 12-54 months since the beginning (median follow up anticipated 3.75 years)
Showing the first 100 of 111 sites across 2 countries. Choose a country and city above to see the rest.
Plan to share: No
Ran from Oct 2018 to primary completion in Jan 2025, 75 months.
Of 83 non-industry phase 4 interventional studies under Myocardial Infarction, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 78. This study's 75 months is above that.
Counting every sponsor, half of 87 studies reached it within 42 months; a quarter within 22 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Beta blockers
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III